Figure 2
From: The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma
(a) The overall survival rates of patients of stage I or II with nasal NK/T cell lymphoma and nasal non-NK/T cell lymphoma. (b) The distant involvement free rates of patients of stage I or II with nasal NK/T cell lymphoma and nasal non-NK/T cell lymphoma.